On October 8, 2026, Editas Medicine, Inc. announced via a Form 8-K filing that it has obtained approval to commence the Phase ...
The effects of disease-associated genetic variants on gene expression and genome accessibility have been analysed together.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results